Please Note:

On September 30, 2004, Vioxx (rofecoxib) was withdrawn from the U.S. and worldwide market because of safety concerns about an increased risk of cardiovascular events. See the FDA Web site for more information” (http://www.fda.gov/medwatch/SAFETY/2004/safety04.htm#vioxx).

Due to this development, please disregard any information in the AGS Guideline on the Management of Persistent Pain in Older Adults regarding the use of VIOXX (refecoxib). The AGS Expert Panel on Persistent Pain will be updating its Guideline recommendations.

The AGS Guideline on the Management of Persistent Pain in Older Persons (2002) (PDF FILE- requires Adobe Acrobat Reader)